Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06787066 · ClinicalTrials.gov registry record · Early Phase 1

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

A Early Phase 1 study of Menopause, sponsored by University of Missouri-Columbia.

Recruiting
Registry status
Early Phase 1
Development phase
75
Enrollment target
1
Study location

NCT06787066 is a Early Phase 1 study of Menopause that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 75 participants, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06787066, a Early Phase 1 study of Menopause, is actively recruiting participants, sponsored by University of Missouri-Columbia.

RECRUITING
Registry status
Early Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

Conditions Studied

Interventions

  • DRUG Propranolol Hydrochloride
  • DRUG Phentolamine Injection

Study Locations (1)

Missouri

  • University of Missouri - Columbia

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-07-10
Est. Completion 2026-12
Phase Early Phase 1

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT06787066

The ClinicalTrials.gov registry entry for NCT06787066 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Propranolol Hydrochloride is the first listed.

NCT06787066 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT06787066 about?

NCT06787066 is a clinical study titled "Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms". The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

What is the current status of trial NCT06787066?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2025-07-10. Estimated completion is 2026-12.

What conditions does trial NCT06787066 study?

This clinical trial studies the following conditions: Menopause.

What interventions are being tested in trial NCT06787066?

The interventions under investigation include: Propranolol Hydrochloride (DRUG), Phentolamine Injection (DRUG).

Who is sponsoring clinical trial NCT06787066?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06787066 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.